Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a primary emphasis on severe genetic skin disorders and related conditions. The QNRX news feed on Stock Titan aggregates company press releases and market-moving updates that shed light on the progress of its clinical pipeline, regulatory interactions and financing activities.
Investors following QNRX news can see detailed updates on the development of the company’s lead asset, QRX003, a topical lotion in late-stage pivotal trials for Netherton Syndrome. Quoin regularly reports clinical data from investigator-led pediatric studies and pivotal programs, describing changes in skin condition, pruritus, sleep disturbance and use of concomitant medications in Netherton Syndrome patients. News items also cover initial positive data in Peeling Skin Syndrome and the potential versatility of QRX003 across multiple rare skin diseases.
Regulatory and designation milestones are another key component of Quoin’s news flow. The company has announced Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for QRX003 in Netherton Syndrome, as well as Rare Pediatric Disease Designation in the United States. These updates provide context on potential market exclusivity and incentives that may affect the long-term outlook for the program.
Quoin’s news also highlights broader corporate developments, including private placement financings with healthcare-focused institutional investors, adoption of equity incentive plans, leadership changes such as the appointment of a new chief financial officer and shareholder meeting outcomes. In addition, the company issues regular communications about its NETHERTON NOW awareness campaign, releasing video episodes that feature patients, advocates and experts discussing the burden of Netherton Syndrome. For readers tracking QNRX, this news stream offers an ongoing view into clinical progress, regulatory events, capital formation and patient advocacy efforts related to Quoin’s rare disease focus.
Quoin Pharmaceuticals (NASDAQ: QNRX) has announced additional clinical evidence regarding QRX003's effectiveness in treating Netherton Syndrome. After observing positive results during a 12-week treatment period, the company reported that all clinical benefits were completely reversed within 4 weeks of treatment discontinuation.
The clinical data shows that the first subject, who received twice-daily doses, experienced significant improvements across all measured endpoints during the treatment period. The Modified Ichthyosis Area of Severity Index (M-IASI) improved from 18 to 3, the Worst Itch Numeric Rating Scale (WINRS) decreased from 7 to 2, and the Investigator's Global Assessment (IGA) improved from Moderate to Almost Clear. However, these metrics reverted to baseline levels after treatment stopped.
The results indicate that chronic, whole-body treatment with QRX003 is necessary for maintaining positive clinical outcomes in Netherton Syndrome patients. Quoin currently has four clinical studies underway, with three under FDA IND applications, aiming to develop the first approved treatment for this condition.
Skinvisible Pharmaceuticals (OTCQB:SKVI) reports significant progress through its licensee Quoin Pharmaceuticals' advancement in Netherton Syndrome treatment. The company's proprietary Invisicare® technology and formulation, licensed to Quoin, has shown positive results in clinical studies. Key developments include FDA clearance for a 'whole body' study at Northwestern University and significant clinical improvements in both open label and pediatric studies, where subjects' conditions improved from 'severe' to 'mild' after 6 weeks of treatment.
The treatment, QRX003, has been licensed in 60 countries with studies expanding to UK, Ireland, and Saudi Arabia. Upon FDA or EU approval, Skinvisible will receive a $5 million milestone payment plus ongoing royalties from sales. No adverse events or safety concerns have been reported in the ongoing clinical studies.
Quoin Pharmaceuticals (NASDAQ: QNRX) reported positive interim clinical data from its ongoing Investigator Pediatric Netherton Syndrome study of QRX003. The study demonstrated significant improvement in treated skin areas, with the subject's condition improving from 'Severe' to 'Mild' after six weeks of twice-daily treatment.
Due to these positive results, the treatment area has been expanded from 20% to the whole body surface area (BSA). No adverse events or safety concerns have been reported, consistent with other ongoing Netherton Syndrome clinical studies. The Investigator's Global Assessment (IGA) showed improvement from 'Severe' at baseline to 'Mild-Moderate' after 12 days, progressing to 'Mild' after 6 weeks.
Quoin Pharmaceuticals announces additional positive interim data from its ongoing open-label Netherton Syndrome clinical study. The study involves QRX003, a treatment administered twice daily. After 12 weeks, the first subject showed significant improvements across all measured clinical endpoints:
- M-IASI: Reduced from 18 to 3 (lower scores indicate improvement)
- WINRS: Decreased from 7 to 2 (measures itch severity on an 11-point scale)
- IGA: Improved from 'Moderate' to 'Almost Clear'
Photographs demonstrating the subject's skin improvements are available on Quoin's website. No safety concerns were identified during the study. Patient satisfaction scores were highly positive and improved further after 12 weeks. Quoin CEO, Dr. Michael Myers, expressed excitement over the results, highlighting the potential efficacy of QRX003 and the absence of safety issues. The company is preparing for a 'whole body' clinical study at Northwestern University, with FDA clearance already obtained. Data from this study will support a New Drug Application for QRX003 as the first approved treatment for Netherton Syndrome. Quoin anticipates providing more updates throughout 2025.
Quoin Pharmaceuticals (NASDAQ: QNRX) has announced pricing of a $6.8 million public offering, consisting of 15,111,110 ordinary shares represented by ADSs (or pre-funded warrants) at $0.45 per ADS. The offering includes Series F and G warrants to purchase up to 15,111,110 ADSs each, with exercise prices of $0.45 per share and expiration periods of 2 and 5 years respectively.
The company plans to use proceeds for general corporate purposes, including operating expenses, R&D, clinical testing, working capital, and potential acquisitions. The offering, which includes participation from executives and directors, is expected to close around December 23, 2024. Additionally, Quoin has modified certain existing warrants, reducing their exercise price from $1.60 to $0.45 per ADS and extending their expiration to December 2029.
Quoin Pharmaceuticals has received FDA clearance to initiate a new clinical study for QRX003, a topical lotion for Netherton Syndrome (NS). This study, conducted by Dr. Amy Paller at Northwestern University, will involve up to eight subjects applying QRX003 twice daily to over 80% of their body surface area for 12 weeks. This extensive application aims to mimic real-world use and generate data for potential regulatory approval. QRX003 targets kallikreins in the skin, responsible for excessive skin shedding in NS. This is Quoin's third clinical study under their open Investigational New Drug application and follows positive interim data from ongoing studies. Quoin aims to deliver the first-ever approved treatment for NS.
Quoin Pharmaceuticals (NASDAQ: QNRX) has reported positive interim data from two ongoing Netherton Syndrome clinical studies for its QRX003 treatment. In the first study, a subject receiving twice-daily dosing showed significant improvements after six weeks: Modified Ichthyosis Area of Severity Index (MIASI) reduced from 18 to 4, Investigator's Global Assessment (IGA) improved from 'moderate' to 'mild', and pruritus assessment decreased from 7 to 4 on the Worst Itch Numeric Rating Scale.
In the second study, a pediatric patient showed marked improvement after just 12 days of treatment, with IGA classification improving from 'severe' to 'mild-moderate'. No safety concerns were reported in either study.
Quoin Pharmaceuticals (NASDAQ: QNRX) reported Q3 2024 developments and financial results. The company initiated a clinical study for QRX003 in Peeling Skin Syndrome in New Zealand and expanded its Netherton Syndrome trials with two new UK sites. Financial results showed a net loss of $2.3 million for Q3 2024, compared to $1.9 million in Q3 2023. Cash position stands at $10.3 million, expected to fund operations into late 2025. The management team made significant insider share purchases, demonstrating confidence in the company's trajectory.
Quoin Pharmaceuticals (NASDAQ: QNRX) has begun testing QRX003 in a pediatric patient with Netherton Syndrome (NS) at Children's Health Ireland in Dublin, led by Dr. Alan Irvine. The company plans to expand testing to include three additional pediatric patients in Spain. QRX003 is currently being evaluated in two late-stage clinical trials, with promising results showing improvement across multiple endpoints and no treatment-related adverse events. The company is expanding its clinical sites beyond the existing five U.S. locations, with new sites planned in Saudi Arabia and two in the United Kingdom.
Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced it will release its third quarter 2024 financial results before market opens on Thursday, November 7, 2024. The announcement will include an operational update on company achievements during the quarter and financial highlights.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
